ArticleStatistics in medicine2024
Modeling Chronic Disease Mortality by Methods From Accelerated Life Testing.
Article in Statistics in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hidden multistate models to study multimorbidity trajectories.Scientific reports · 2026Article
- A New Parametric Accelerated Failure Time Model for Semi-Competing Risks Data.Statistics in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We propose a parametric model for describing chronic disease mortality from cohort data and illustrate its use for Type 2 diabetes. The model uses ideas from accelerated life testing in reliability theory and conceptualizes the occurrence of a chronic disease as putting the observational unit to an enhanced stress level, which is supposed to shorten its lifetime. It further addresses the issue of semi-competing risk, that is, the asymmetry of death and diagnosis of disease, where the disease can be diagnosed before death, but not after. With respect to the cohort structure of the data, late entry into the cohort is taken into account and prevalent as well as incident cases inform the analysis. We finally give an extension of the model that allows age at disease diagnosis to be observed not exactly, but only partially within an interval. Model parameters can be straightforwardly estimated by Maximum Likelihood, using the assumption of a Gompertz distribution we show in a small simulation study that this works well. Data of the Cardiovascular Disease, Living and Ageing in Halle (CARLA) study, a population-based cohort in the city of Halle (Saale) in the eastern part of Germany, are used for illustration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.